Anticoagulation in Surgery

Ajita Naik MBBS^1*, Mohamed Rahouma MD^*1,2, Ihab Eldesoki MD³, Mohamed Kamel MD^1,2, Maha Yehia MD³, Kritika Mehta MBBS¹, Massimo Baudo MD¹, Matthew Henry MD¹, Nagla Abdelkareem MD⁴, Abdelrahman Mohamed MD², Leonard Girardi MD¹ & Mario Gaudino MD, FEBCTS¹

¹Cardiothoracic surgery Department, Weill Cornell Medicine/New York Presbyterian Hospital, NY/USA
²Surgical Oncology Department, National Cancer Institute, Cairo University/Egypt
³Medical Oncology Department, National Cancer Institute, Cairo University/Egypt
⁴Medical Oncology Department, University of Cincinnati Cancer Institute, Cincinnati, Ohio/USA

Mohamed Rahouma, Cardiothoracic surgery Department, Weill Cornell Medicine/New York Presbyterian Hospital, NY/USA.

Keywords: Anticoagulation; Hypercoagulability; Haemorrhage; Thromboembolism

Abstract

We reviewed available data in the current trends in the anticoagulants use in patients undergoing surgery in addition to hypercoagulability management in patients with malignancy. There is a comparison between oral anticoagulants vs conventional methods of thrombosis prevention as warfarin vs. other methods like anti-platelet drugs like aspirin and clopidogrel. We found that current data suggests that oral anticoagulants provide superior outcomes compared to other options.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).